MENU

Can Novavax (NVAX) Stock Reach $14?

a company which engages in development of novel recombinant vaccines

Industry: #Biotechnology
A.I.Advisor
published price charts
A.I.Advisor
Nov 11, 2026

Can Novavax (NVAX) Stock Reach $14?

Key Takeaways

  • The central $14 stock price target is the arithmetic mean of nine verified analyst price targets, rounded from roughly $13.78.
  • With NVAX last trading near $10.20, reaching $14 would require an upside of roughly 37%.
  • The analyst range is unusually wide, from $6 (J.P. Morgan) to $25 (Jefferies), reflecting sharp disagreement over the company's post-COVID transition.
  • Supporting factors include the Sanofi partnership, milestone and royalty payments, a licensing-driven model, and a cash runway extended into 2029.
  • Key risks are declining revenue, reliance on partner execution, negative stockholders' equity, and persistent cash burn.
  • The Major News, Today's Price Move, Forecast, and Earnings pages offer additional detail on this ticker's developments, price action, and outlook.
  • For AI-driven market ideas across thousands of stocks and ETFs, explore Trending AI Robots.

Analyst Price Targets and Consensus View

Novavax, Inc. (NVAX) is a Gaithersburg, Maryland-based biotechnology company that develops and commercializes vaccines, including its Nuvaxovid COVID-19 vaccine and its Matrix-M adjuvant. Nine credible, current analyst price targets were reviewed to establish the central target. They span a very wide range of $6 to $25, and their arithmetic mean of about $13.78 rounds to a central target of $14.

The dispersion is the story. On the bullish side, Jefferies holds a $25 target (maintained in March 2026) and views Novavax as a capital-light adjuvant platform rather than merely a COVID-royalty story. Cantor Fitzgerald ($18), BTIG ($19), H.C. Wainwright ($16), and B. Riley Securities ($16, trimmed from $18 in November 2026) carry Buy ratings. On the cautious side, TD Cowen ($9, Hold), Bank of America ($8, Sell), Citigroup ($8, Sell), and J.P. Morgan ($6, Sell) emphasize shrinking revenue, cash burn, and execution risk. The mean should be read as a midpoint across genuinely divergent views, not as a guarantee.

Current Market Position and Path Toward the Target

Novavax shares closed near $10.20 on November 10, 2026, giving the company a market capitalization of roughly $1.7 billion. Reaching $14 would require an advance of about 37%, which qualifies as a substantial move. The stock's 52-week range is approximately $6.20 to $13.39.

The path would likely depend on continued execution of a licensing and royalty model built around Sanofi, which triggered a $125 million milestone payment in late 2026 when it launched a Phase 3 influenza-COVID-19 combination vaccine trial in Europe. Novavax reported third-quarter 2026 revenue of $68.3 million and a sharply narrowed net loss of $31.4 million, and management has pointed to a cash runway into 2029. Still, revenue is contracting from a 2025 peak of about $1.12 billion, and the company is not yet consistently profitable on a GAAP (generally accepted accounting principles) basis.

What Could Support a Move Toward the Target

  • The Sanofi partnership provides milestone payments and potential royalties, and a combination flu-COVID product could expand a large addressable market.
  • A licensing-heavy model and additional partnerships (including Pfizer and Takeda) offer capital-efficient, non-dilutive revenue.
  • A cash runway into 2029 and reduced operating costs improve financial flexibility.
  • Strong 2025 results demonstrated that the company can convert vaccine revenue into profit under the right conditions.

What Could Prevent the Target From Being Reached

  • Revenue is forecast to decline, and the company has returned to losses after a profitable 2025.
  • Negative stockholders' equity and ongoing cash burn leave a thinner balance-sheet cushion.
  • Value creation depends heavily on partners hitting regulatory and commercial milestones, which carries timing risk.
  • Competition from mRNA vaccine makers and uncertain demand for COVID and combination vaccines could compress royalties.

Technical Levels and Market Structure

The stock trades below its 50-day moving average near $10.61 but above its 200-day moving average near $9.34. The 52-week high near $13.39, set in early October 2026, stands as the nearest major resistance before the $14 target. Support sits around the $10 psychological level and the 200-day average near $9.34, with the 52-week low near $6.20 farther below.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms vary. Investors should watch quarterly earnings and guidance, Sanofi's combination-vaccine clinical and commercial progress, milestone and royalty recognition, analyst target revisions, and any changes in partnership terms or the broader biotechnology funding environment.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. For those following names like Novavax alongside the broader market, the signals offer a way to stay current on daily developments without constant chart watching.

Final Assessment

The $14 central target is the average of nine verified analyst price targets spanning $6 to $25, and it implies a substantial gain of roughly 37% from a price near $10.20. The bull case rests on Sanofi milestones, royalties, and a capital-light licensing model, while the bear case centers on contracting revenue, cash burn, and dependence on partner execution. With such a wide analyst range, the target is best understood as a midpoint across competing narratives rather than a forecast. Investors should monitor partnership milestones, quarterly results, and analyst revisions as the key inputs to whether the shares can close the gap toward $14.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

NVAX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with CRSP. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-2.68%
CRSP - NVAX
54%
Loosely correlated
-0.89%
ARCT - NVAX
51%
Loosely correlated
-0.95%
RXRX - NVAX
49%
Loosely correlated
-4.35%
MRNA - NVAX
48%
Loosely correlated
-3.45%
PCVX - NVAX
48%
Loosely correlated
-2.04%
More
Can Novavax (NVAX) Stock Reach $14?